| Market Cap | 9.22M | P/E | - | EPS this Y | 53.50% | Ern Qtrly Grth | - |
| Income | -7.29M | Forward P/E | -0.61 | EPS next Y | 31.20% | 50D Avg Chg | -7.00% |
| Sales | 18.6k | PEG | - | EPS past 5Y | - | 200D Avg Chg | -29.00% |
| Dividend | N/A | Price/Book | 38.70 | EPS next 5Y | - | 52W High Chg | -79.00% |
| Recommedations | 2.00 | Quick Ratio | 3.21 | Shares Outstanding | 0.91M | 52W Low Chg | 25.00% |
| Insider Own | 10.64% | ROA | -81.69% | Shares Float | 826.30K | Beta | 3.16 |
| Inst Own | 1.12% | ROE | -269.29% | Shares Shorted/Prior | 104.87K/44.99K | Price | 0.89 |
| Gross Margin | 67.31% | Profit Margin | - | Avg. Volume | 70,109 | Target Price | 13.50 |
| Oper. Margin | -37,907.43% | Earnings Date | - | Volume | 11,859 | Change | -2.05% |
Heart Test Laboratories, Inc., doing business as HeartSciences, is a medical technology company focuses on applying AI-based technology to an ECG to expand and improve an ECG's clinical utility. It is developing AI-ECG solutions, a proprietary algorithm designed to detect impaired cardiac relaxation, or cardiac dysfunction, caused by heart disease and/or age-related cardiac dysfunction; MyoVista wavECG, a resting 12-lead ECG that will incorporate its AI-ECG algorithm that provides diagnostic information related to cardiac dysfunction and conventional ECG information in the same test; and MyoVista Insights, a cloud-based platform to host AI-ECG algorithms on an ECG hardware agnostic basis. The company is doing business as HeartSciences. Heart Test Laboratories, Inc. was incorporated in 2007 and is headquartered in Southlake, Texas.
| Ascendiant Capital | Buy | Sep 23, 24 |
| Ascendiant Capital | Buy | Jan 30, 23 |
| Maxim Group | Buy | Dec 19, 22 |
| Maxim Group | Buy | Nov 9, 22 |
| Benchmark | Speculative Buy | Aug 8, 22 |